<DOC>
	<DOCNO>NCT01852214</DOCNO>
	<brief_summary>Patients diabetes mellitus ( DM ) increase risk adverse atherothrombotic event . This may part attribute fact patient reduce response oral antiplatelet medication , particular P2Y12 receptor inhibitor clopidogrel , use secondary prevention ischemic event . Prasugrel ticagrelor recently approve P2Y12 receptor inhibitor , compare clopidogrel , potent antiplatelet effect . Head-to-head comparison two drug lack .</brief_summary>
	<brief_title>Pharmacodynamic Effect Prasugrel vs. Ticagrelor Diabetes</brief_title>
	<detailed_description>Patients diabetes mellitus ( DM ) increase risk adverse atherothrombotic event . This may part attribute fact patient reduce response oral antiplatelet medication , particular P2Y12 receptor inhibitor clopidogrel , use secondary prevention ischemic event . Upregulation platelet P2Y12 receptor mediate signal show DM patient may contribute pharmacodynamic observation , suggest need potent P2Y12 inhibiting strategy patient . Prasugrel ticagrelor recently approve P2Y12 receptor inhibitor , compare clopidogrel , potent antiplatelet effect . Therefore , prasugrel ticagrelor represent attractive treatment option patient DM . This also support DM sub-group analysis pivotal TRITON-TIMI 38 ( Trial Assess Improvement Therapeutic Outcomes Optimizing Platelet Inhibition Prasugrel-Thrombolysis Myocardial Infarction ) PLATO ( Platelet Inhibition Patient Outcomes ) trial , lead approval prasugrel ticagrelor , respectively . Although result sub-group analysis suggest prasugrel associate enhanced benefit DM patient , ticagrelor effect DM patient consistent overall study population , head-to-head comparison two drug elucidate exert differential effect platelet DM patient . However , pharmacodynamic study compare prasugrel ticagrelor DM patient lack . The ever grow DM population high risk recurrent atherothrombotic event underscore need define antiplatelet treatment strategy lead optimal platelet inhibition patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients know ( angiographically document ) CAD . On maintenance treatment aspirin ( 81 mg per day ) least 1month per standard care . Type 2 DM treatment oral hypoglycemic agent and/or insulin . Age 18 74 year old . History stroke , transient ischemic attack intracranial bleeding . On treatment P2Y12 receptor antagonist ( ticlopidine , clopidogrel , prasugrel , ticagrelor ) . Known allergy aspirin , ticlopidine , clopidogrel , prasugrel , ticagrelor . Weight &lt; 60kg . On treatment oral anticoagulant ( Vitamin K antagonist , dabigatran ) . Blood dyscrasia bleed diathesis . Platelet count &lt; 80x106/mL . Hemoglobin &lt; 10 g/dL . Active bleed hemodynamic instability . Creatinine Clearance &lt; 30 mL/minute . Baseline ALT &gt; 2.5 time upper limit normal . Hb A1c â‰¥ 10 mg/dL within 3 month . Patients sick sinus syndrome ( SSS ) high degree AV block without pacemaker protection . Drugs interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromizycin . Pregnant females* . Women childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
</DOC>